KEYNOTE-B98: Phase Ib/II study of pembrolizumab plus investigational agents as second-line treatment for anti-PD-1/PD-L1-refractory extensive-stage small cell lung cancer (ES-SCLC)

被引：0
|
作者：
Lai, W. C. V. [1 ]
Ahn, M-J. [2 ]
Shentzer, T. [3 ]
Kowalski, D. [4 ]
Cho, B. C. [5 ]
Schmid, S. [6 ]
Jove, M. [7 ]
Huang, M. [8 ]
Zhao, B. [8 ]
El-Osta, H. [8 ]
Navarro, A. [9 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, 1275 York Ave, New York, NY 10021 USA
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[3] Rambam Med Ctr, Dept Med Oncol, Haifa, Israel
[4] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Med Oncol, Warsaw, Poland
[5] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[6] Kantonsspital St Gallen, Dept Med Oncol, St Gallen, Switzerland
[7] Inst Catala Oncol, Barcelona, Spain
[8] Merck & Co Inc, Kenilworth, NJ USA
[9] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.134
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
116TiP
引用
收藏
页码：S1425 / S1426
页数：2
相关论文
共 50 条
  • [21] Real-world evidence of cancer immunotherapy (CIT) combination treatment in first-line (1L) extensive-stage small cell lung cancer (ES-SCLC).
    Nadler, Eric S.
    Vasudevan, Anupama
    Davies, Kalatu
    Wang, Yunfei
    Johnson, Ann
    Ogale, Sarika
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] Effectiveness and safety of anlotinib plus anti-programmed cell death 1/ligand 1 (anti-PD-1/PD-L1) antibodies as maintenance therapy after first-line chemotherapy combined with anti-PD-1/ PD-L1 antibodies in extensive-stage small cell lung cancer: a real world study
    Yang, Pan
    Luo, Hu
    Zhao, Lintao
    Xiong, Fu
    Tang, Chunlan
    JOURNAL OF THORACIC DISEASE, 2024, 16 (07) : 4391 - 4399
  • [23] Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as fi rst-line therapy for extensive-stage small-cell - cell lung cancer (ES-SCLC): a phase II trial
    Chen, Dawei
    Zou, Bing
    Li, Butuo
    Gao, Aiqin
    Huang, Wei
    Shao, Qian
    Meng, Xiangjiao
    Zhang, Pinliang
    Tang, Xiaoyong
    Hu, Xudong
    Zhang, Yan
    Guo, Jun
    Zhao, Changhong
    Yuan, Jiajia
    Li, Qian
    Zhu, Changbin
    Yu, Jinming
    Wang, Linlin
    ECLINICALMEDICINE, 2024, 75
  • [24] Phase Ib study of CC-90011 plus etoposide and cisplatin (EP) in patients with first-line extensive-stage (ES) small cell lung cancer (SCLC)
    Paz-Ares, L.
    Juan-Vidal, O.
    Carcereny, E.
    Greillier, L.
    Navarro, A.
    Bennouna, J.
    Santoro, A.
    Berardi, R.
    Besse, B.
    Salvagni, S.
    Gonzalez, H.
    de Alvaro, J.
    Parra-Palau, J.
    Sanchez-Perez, T.
    Aronchik, I.
    Filvaroff, E.
    Lamba, M.
    Nikolova, Z.
    Ponce, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S482 - S483
  • [25] Carfilzomib (CFZ), carboplatin and etoposide for previously untreated extensive-stage small cell lung cancer (ES-SCLC): Phase 1b results from a phase 1b/2 study.
    Badin, Firas Benyamine
    Chiang, Anne C.
    Fisher, William B.
    Orlov, Sergey
    Harper, Harry D.
    Eskander, Elhamy
    Harb, Wael A.
    Kio, Ebenezer
    Gopalan, Priya Kadambi
    Haggstrom, Daniel Ernest
    Burdaeva, Olga
    Zahlten-Kumeli, Anita
    Aggarwal, Sanjay
    Obreja, Mihaela
    Gorbunova, Vera
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC): Preliminary results from the phase II TROPiCS-03 basket trial
    Dowlati, A.
    Cervantes, A.
    Babu, S.
    Hamilton, E. P.
    Wong, S. F.
    Tazbirkova, A.
    Sullivan, I. G.
    de Lummen, C. Van Marcke
    Italiano, A.
    Patel, J.
    Mekan, S.
    Wu, T.
    Chiang, A. C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1061 - S1062
  • [27] Durvalumab (D) plus platinum-etoposide (EP) in 1L extensive-stage small-cell lung cancer (ES-SCLC): Exploratory analysis of SCLC molecular subtypes in CASPIAN
    Xie, Mingchao
    Chugh, Priti
    Broadhurst, Helen
    Lai, Zhongwu
    Whitston, David
    Paz-Ares, Luis
    Gay, Carl
    Byers, Lauren
    Rudin, Charles M.
    Stewart, Ross
    Barrett, J. Carl
    Shrestha, Yashaswi
    Panse, Jens
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 145 - 145
  • [28] A phase II randomized study of BMS-986012, an anti-fucosyl-GM1 monoclonal antibody, plus carboplatin, etoposide, and nivolumab (NIVO) as first-line (1L) therapy in patients with extensive-stage small cell lung cancer (ES-SCLC)
    Chu, Q.
    Parikh, K.
    Paz-Ares, L.
    Navarro, A.
    Markman, B.
    Sarmiento, R.
    Kollia, G.
    He, C.
    Sanghavi, K.
    Chang, H.
    Fischer, B.
    Guha, U.
    Tannenbaum-Dvir, S.
    Wu, K.
    Liu, Y.
    Ready, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S1170 - S1170
  • [29] Durvalumab (D) plus platinum-etoposide (EP) in 1L extensive-stage small-cell lung cancer (ES-SCLC): Exploratory analysis of SCLC molecular subtypes in CASPIAN
    Xie, Mingchao
    Chugh, Priti
    Broadhurst, Helen
    Lai, Zhongwu
    Whitston, David
    Paz-Ares, Luis
    Gay, Carl
    Byers, Lauren
    Rudin, Charles M.
    Stewart, Ross
    Barrett, J. Carl
    Shrestha, Yashaswi
    CANCER RESEARCH, 2022, 82 (12)
  • [30] PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients
    Zeng, Ran
    Liu, Fang
    Fang, Chen
    Yang, Jin
    Luo, Lifeng
    Yue, Ping
    Gao, Beili
    Dong, Yuchao
    Xiang, Yi
    FRONTIERS IN IMMUNOLOGY, 2021, 12
12345